HOME >> MEDICINE >> NEWS
Potent spice works to block growth of melanoma in lab test

HOUSTON - Curcumin, the pungent yellow spice found in both turmeric and curry powders, blocks a key biological pathway needed for development of melanoma and other cancers, say researchers from The University of Texas M. D. Anderson Cancer Center.

The study, to be published in the August 15, 2005 issue of the journal Cancer, but available on line at 12:01 a.m. (EDT) on Monday, July 11, demonstrates how curcumin stops laboratory strains of melanoma from proliferating and pushes the cancer cells to commit suicide.

It does this, researchers say, by shutting down nuclear factor-kappa B (NF-kB), a powerful protein known to promote an abnormal inflammatory response that leads to a variety of disorders, including arthritis and cancer.

The study is the latest to suggest that curcumin has potent anticancer powers, say the researchers.

"The antioxidant, anti-inflammatory and anti-carcinogenic properties of curcumin derived from turmeric are undergoing intense research here and at other places worldwide," says one of the study's authors, Bharat B. Aggarwal, Ph.D., professor of cancer medicine in the Department of Experimental Therapeutics.

At M. D. Anderson, for example, dramatic results from laboratory studies have led to two ongoing Phase I human clinical trials, testing the ability of daily capsules of curcumin powder to retard growth of pancreatic cancer and multiple myeloma. Another Phase I trial is planned for patients with breast cancer, and given this news of curcumin's activity in melanoma, animal studies will soon begin, Aggarwal says.

Ground from the root of the Curcuma longa plant, curcumin is a member of the ginger family. It has long been utilized in India and other Asian nations for multiple uses: as a food-preservative, a coloring agent, a folk medicine to cleanse the body, and as a spice to flavor food (two to five percent of turmeric is curcumin, for example).

While researchers had thought curcumin prima
'"/>

Contact: Heather Sessions
hrsessions@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
11-Jul-2005


Page: 1 2 3

Related medicine news :

1. Potential prostate cancer treatment improvements discovered by researchers at Cedars-Sinai
2. Potential heart benefit found in stem cells
3. Potential association between skin cancer cream and improvements of prematurely aged skin
4. Potential treatment for intracerebral hemorrhage under study
5. Potential pharmaceutical drugs in the field of cancer
6. Potential new treatment for insulin-dependent diabetes
7. Potential weak link between virus and liver cancer discovered
8. Improving coping skills benefits family caregivers of hospice patients with cancer
9. Hospice referral rates increase with intervention improving communication
10. New research discovers independent brain networks control human walking
11. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Potent spice works block growth melanoma lab test

(Date:3/6/2015)... Lewisville, Texas (PRWEB) March 06, 2015 ... at 7am today. The new facility is located at 13351 ... , “Our experienced clinical team is ready 24-7 to provide ... said Dr. Grossman, Facility Medical Director of First Choice Emergency ... a ribbon cutting with the South Metro Denver Chamber of ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Utilizing the ... and rapidly reach their ideal weight has enabled Diet ... to their already impressive collection of fat loss ... existing clients special promotions and savings to help people ... immediately. This promotion is especially appealing to new ...
(Date:3/6/2015)... Aliso Viejo, California (PRWEB) March 06, 2015 ... entitled Pro3rd Hue from Pixel Film Studios. , “Pro3rd Hue ... style.” Said Christina Austin, CEO of Pixel Film Studios. “Blurring ... definite game changer.” , Pro3rd Hue is a set of ... Final Cut Pro X. With Pro3rd Hue, FCPX users can ...
(Date:3/6/2015)... Medical Products, Inc., a Mississippi Corporation, announced ... Healthcare to become an authorized distributor for GE Healthcare ... has 31 years in distribution within the U.S. and ... agreement, MPI will have the opportunity to extend services ... , MPI has always strived to provide our customers ...
(Date:3/5/2015)... global digital PCR (dPCR) and qPCR market is expected to reach ... 2019. , The global digital PCR (dPCR) and qPCR market is ... 2019. Although the mature markets such as the U.S., Germany, France ... qPCR market the Asia-Pacific region is expected to grow at the ... the digital PCR (dPCR) and qPCR market is driven by factors ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4
(Date:3/5/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... its financial results for the fourth quarter and full ... , Net Revenues Increased 21.3% Year Over Year to ... 17.7% Year Over Year to $140.5 Million , ...
(Date:3/5/2015)... and TÜBINGEN, Germany , March ... Gates Foundation and CureVac today announced that the ... million (€46 million) in CureVac, a leading clinical-stage ... part of the agreement, the foundation will also ... prophylactic vaccines based on CureVac,s proprietary messenger RNA ...
(Date:3/5/2015)... LITTLE FALLS, N.J. , March 5, 2015 ... the results for its second quarter ended January 31, 2015 ... a conference call to discuss the results at 11:00 AM ... dial (877) 407-8033 approximately 5 to 10 minutes before the ... a digital replay of the call will be available from ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
Cached News: